Biogen's Phase 2 data for BIV80 is pivotal because its antisense mechanism targets Tau at the mRNA level, reducing all forms of the protein. This "turns off the faucet" approach provides a broad, definitive test of whether targeting Tau itself is a viable strategy for Alzheimer's, bypassing the complexity of its various forms.
Related Insights
The foundational discovery of the toxic alpha-sheet structure was first identified via computer simulations because it was impossible to characterize experimentally. This computational hypothesis then required 15 years of wet lab work to validate, highlighting the power of in-silico methods to pioneer novel drug targets.
Novo Nordisk ran a nearly 4,000-patient Phase 3 Alzheimer's trial despite publicly stating it had a low probability of success. This strategy consumes valuable patient resources, raising ethical questions about whether a smaller, definitive Phase 2 study would have been a more responsible approach for the broader research ecosystem.
The most important upcoming catalyst in neuroscience is Eli Lilly's TRAILBLAZER-ALZ 3 study, which aims to prevent Alzheimer's in at-risk patients. A positive result is expected to show a much larger effect size than seen in treating existing disease, potentially creating a massive new market and shifting the entire neurodegenerative paradigm.
Similar to how Gilead was viewed before its stock surge, Biogen is seen as a sleepy big-cap with a declining core business. However, it has several underappreciated near-term catalysts in Alzheimer's (tau program), SLE, and lupus that could re-rate the stock.
Unlike sedatives, DORA-class sleep aids (Dual Orexin Receptor Antagonists) work by inhibiting wakefulness, creating more natural sleep architecture. Research suggests this may improve the brain's ability to clear beta-amyloid and tau proteins linked to Alzheimer's disease, offering a potential preventative strategy.
Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.
Alt-Pep's SOBA blood test is a crucial companion diagnostic for its SOBIN-AD therapeutic. It allows for patient stratification by confirming the presence of the drug's target—toxic oligomers. This creates a rare, direct link between biomarker, target, and mechanism, significantly increasing the probability of clinical success.
After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.
The long-term vision for Alt-Pep's diagnostic extends beyond symptomatic patients or those with family histories. The goal is for it to become a routine screening assay, administered annually to the general population to catch the disease at its earliest molecular stages, changing the paradigm from treatment to prevention.
Antibodies bind to specific amino acid sequences, making them unable to distinguish between a protein's healthy and toxic structural forms. Alt-Pep's synthetic peptides use a complementary structure (alpha-sheet) to selectively bind only the toxic oligomers, enabling both targeted therapy and highly specific diagnostics.